nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferiprone—Mental disorder—Imiquimod—skin cancer	0.00343	0.00343	CcSEcCtD
Deferiprone—Malnutrition—Imiquimod—skin cancer	0.00341	0.00341	CcSEcCtD
Deferiprone—Arthralgia—Vemurafenib—skin cancer	0.0034	0.0034	CcSEcCtD
Deferiprone—Diplopia—Temozolomide—skin cancer	0.00339	0.00339	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00338	0.00338	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.00337	0.00337	CcSEcCtD
Deferiprone—Vomiting—Vismodegib—skin cancer	0.00335	0.00335	CcSEcCtD
Deferiprone—Rash—Vismodegib—skin cancer	0.00333	0.00333	CcSEcCtD
Deferiprone—Dermatitis—Vismodegib—skin cancer	0.00332	0.00332	CcSEcCtD
Deferiprone—Pancytopenia—Bleomycin—skin cancer	0.0033	0.0033	CcSEcCtD
Deferiprone—Back pain—Imiquimod—skin cancer	0.00329	0.00329	CcSEcCtD
Deferiprone—Blood bilirubin increased—Docetaxel—skin cancer	0.00328	0.00328	CcSEcCtD
Deferiprone—Anaphylactic shock—Vemurafenib—skin cancer	0.00326	0.00326	CcSEcCtD
Deferiprone—Infection—Vemurafenib—skin cancer	0.00324	0.00324	CcSEcCtD
Deferiprone—Cardiac failure—Fluorouracil—skin cancer	0.0032	0.0032	CcSEcCtD
Deferiprone—Nervous system disorder—Vemurafenib—skin cancer	0.0032	0.0032	CcSEcCtD
Deferiprone—Skin disorder—Vemurafenib—skin cancer	0.00317	0.00317	CcSEcCtD
Deferiprone—Dehydration—Temozolomide—skin cancer	0.00315	0.00315	CcSEcCtD
Deferiprone—Nausea—Vismodegib—skin cancer	0.00313	0.00313	CcSEcCtD
Deferiprone—Osteoarthritis—Fluorouracil—skin cancer	0.00312	0.00312	CcSEcCtD
Deferiprone—Pneumonia—Bleomycin—skin cancer	0.00311	0.00311	CcSEcCtD
Deferiprone—Pulmonary embolism—Docetaxel—skin cancer	0.00311	0.00311	CcSEcCtD
Deferiprone—Pancytopenia—Dactinomycin—skin cancer	0.00308	0.00308	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.00305	0.00305	CcSEcCtD
Deferiprone—Hypotension—Vemurafenib—skin cancer	0.00305	0.00305	CcSEcCtD
Deferiprone—Neutropenia—Dactinomycin—skin cancer	0.00303	0.00303	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Temozolomide—skin cancer	0.00299	0.00299	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00297	0.00297	CcSEcCtD
Deferiprone—Convulsion—Imiquimod—skin cancer	0.00295	0.00295	CcSEcCtD
Deferiprone—Hypertension—Imiquimod—skin cancer	0.00294	0.00294	CcSEcCtD
Deferiprone—Pneumonia—Dactinomycin—skin cancer	0.0029	0.0029	CcSEcCtD
Deferiprone—Arthralgia—Imiquimod—skin cancer	0.0029	0.0029	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00288	0.00288	CcSEcCtD
Deferiprone—Discomfort—Imiquimod—skin cancer	0.00287	0.00287	CcSEcCtD
Deferiprone—Decreased appetite—Vemurafenib—skin cancer	0.00283	0.00283	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00281	0.00281	CcSEcCtD
Deferiprone—Fatigue—Vemurafenib—skin cancer	0.00281	0.00281	CcSEcCtD
Deferiprone—Pancytopenia—Temozolomide—skin cancer	0.00278	0.00278	CcSEcCtD
Deferiprone—Infection—Imiquimod—skin cancer	0.00276	0.00276	CcSEcCtD
Deferiprone—Neutropenia—Temozolomide—skin cancer	0.00274	0.00274	CcSEcCtD
Deferiprone—Nervous system disorder—Imiquimod—skin cancer	0.00273	0.00273	CcSEcCtD
Deferiprone—Skin disorder—Imiquimod—skin cancer	0.0027	0.0027	CcSEcCtD
Deferiprone—Agranulocytosis—Dactinomycin—skin cancer	0.00269	0.00269	CcSEcCtD
Deferiprone—Sepsis—Docetaxel—skin cancer	0.00269	0.00269	CcSEcCtD
Deferiprone—Hyperhidrosis—Imiquimod—skin cancer	0.00269	0.00269	CcSEcCtD
Deferiprone—Photosensitivity reaction—Temozolomide—skin cancer	0.00267	0.00267	CcSEcCtD
Deferiprone—Weight increased—Temozolomide—skin cancer	0.00267	0.00267	CcSEcCtD
Deferiprone—Pneumonia—Temozolomide—skin cancer	0.00263	0.00263	CcSEcCtD
Deferiprone—Infestation NOS—Temozolomide—skin cancer	0.00261	0.00261	CcSEcCtD
Deferiprone—Infestation—Temozolomide—skin cancer	0.00261	0.00261	CcSEcCtD
Deferiprone—Hepatitis—Dactinomycin—skin cancer	0.00259	0.00259	CcSEcCtD
Deferiprone—Body temperature increased—Vemurafenib—skin cancer	0.00258	0.00258	CcSEcCtD
Deferiprone—Pharyngitis—Dactinomycin—skin cancer	0.00257	0.00257	CcSEcCtD
Deferiprone—Pancytopenia—Fluorouracil—skin cancer	0.00256	0.00256	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00253	0.00253	CcSEcCtD
Deferiprone—Chills—Bleomycin—skin cancer	0.00249	0.00249	CcSEcCtD
Deferiprone—Somnolence—Imiquimod—skin cancer	0.00247	0.00247	CcSEcCtD
Deferiprone—Hepatobiliary disease—Temozolomide—skin cancer	0.00247	0.00247	CcSEcCtD
Deferiprone—Photosensitivity reaction—Fluorouracil—skin cancer	0.00246	0.00246	CcSEcCtD
Deferiprone—Dyspepsia—Imiquimod—skin cancer	0.00245	0.00245	CcSEcCtD
Deferiprone—Pneumonia—Fluorouracil—skin cancer	0.00242	0.00242	CcSEcCtD
Deferiprone—Decreased appetite—Imiquimod—skin cancer	0.00242	0.00242	CcSEcCtD
Deferiprone—Infestation NOS—Fluorouracil—skin cancer	0.00241	0.00241	CcSEcCtD
Deferiprone—Infestation—Fluorouracil—skin cancer	0.00241	0.00241	CcSEcCtD
Deferiprone—Hypersensitivity—Vemurafenib—skin cancer	0.0024	0.0024	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Imiquimod—skin cancer	0.0024	0.0024	CcSEcCtD
Deferiprone—Fatigue—Imiquimod—skin cancer	0.0024	0.0024	CcSEcCtD
Deferiprone—Atrial fibrillation—Docetaxel—skin cancer	0.00238	0.00238	CcSEcCtD
Deferiprone—Pain—Imiquimod—skin cancer	0.00238	0.00238	CcSEcCtD
Deferiprone—Hepatitis—Temozolomide—skin cancer	0.00234	0.00234	CcSEcCtD
Deferiprone—Asthenia—Vemurafenib—skin cancer	0.00234	0.00234	CcSEcCtD
Deferiprone—Pharyngitis—Temozolomide—skin cancer	0.00233	0.00233	CcSEcCtD
Deferiprone—Chills—Dactinomycin—skin cancer	0.00233	0.00233	CcSEcCtD
Deferiprone—Urinary tract disorder—Temozolomide—skin cancer	0.00232	0.00232	CcSEcCtD
Deferiprone—Oedema peripheral—Temozolomide—skin cancer	0.00231	0.00231	CcSEcCtD
Deferiprone—Cardiac failure—Docetaxel—skin cancer	0.00231	0.00231	CcSEcCtD
Deferiprone—Pruritus—Vemurafenib—skin cancer	0.00231	0.00231	CcSEcCtD
Deferiprone—Connective tissue disorder—Temozolomide—skin cancer	0.0023	0.0023	CcSEcCtD
Deferiprone—Urethral disorder—Temozolomide—skin cancer	0.0023	0.0023	CcSEcCtD
Deferiprone—Gastrointestinal pain—Imiquimod—skin cancer	0.00227	0.00227	CcSEcCtD
Deferiprone—Epistaxis—Fluorouracil—skin cancer	0.00227	0.00227	CcSEcCtD
Deferiprone—Pain in extremity—Docetaxel—skin cancer	0.00225	0.00225	CcSEcCtD
Deferiprone—Agranulocytosis—Fluorouracil—skin cancer	0.00225	0.00225	CcSEcCtD
Deferiprone—Diarrhoea—Vemurafenib—skin cancer	0.00223	0.00223	CcSEcCtD
Deferiprone—Urticaria—Imiquimod—skin cancer	0.00221	0.00221	CcSEcCtD
Deferiprone—Abdominal pain—Imiquimod—skin cancer	0.0022	0.0022	CcSEcCtD
Deferiprone—Body temperature increased—Imiquimod—skin cancer	0.0022	0.0022	CcSEcCtD
Deferiprone—Eye disorder—Temozolomide—skin cancer	0.00219	0.00219	CcSEcCtD
Deferiprone—Cardiac disorder—Temozolomide—skin cancer	0.00218	0.00218	CcSEcCtD
Deferiprone—Pharyngitis—Fluorouracil—skin cancer	0.00214	0.00214	CcSEcCtD
Deferiprone—Angiopathy—Temozolomide—skin cancer	0.00213	0.00213	CcSEcCtD
Deferiprone—Immune system disorder—Temozolomide—skin cancer	0.00212	0.00212	CcSEcCtD
Deferiprone—Mediastinal disorder—Temozolomide—skin cancer	0.00211	0.00211	CcSEcCtD
Deferiprone—Chills—Temozolomide—skin cancer	0.0021	0.0021	CcSEcCtD
Deferiprone—Dehydration—Docetaxel—skin cancer	0.0021	0.0021	CcSEcCtD
Deferiprone—Vomiting—Vemurafenib—skin cancer	0.00207	0.00207	CcSEcCtD
Deferiprone—Rash—Vemurafenib—skin cancer	0.00206	0.00206	CcSEcCtD
Deferiprone—Mental disorder—Temozolomide—skin cancer	0.00205	0.00205	CcSEcCtD
Deferiprone—Dermatitis—Vemurafenib—skin cancer	0.00205	0.00205	CcSEcCtD
Deferiprone—Hypersensitivity—Imiquimod—skin cancer	0.00205	0.00205	CcSEcCtD
Deferiprone—Headache—Vemurafenib—skin cancer	0.00204	0.00204	CcSEcCtD
Deferiprone—Malnutrition—Temozolomide—skin cancer	0.00204	0.00204	CcSEcCtD
Deferiprone—Discomfort—Bleomycin—skin cancer	0.00204	0.00204	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00203	0.00203	CcSEcCtD
Deferiprone—Asthenia—Imiquimod—skin cancer	0.00199	0.00199	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00199	0.00199	CcSEcCtD
Deferiprone—Anaphylactic shock—Bleomycin—skin cancer	0.00197	0.00197	CcSEcCtD
Deferiprone—Back pain—Temozolomide—skin cancer	0.00197	0.00197	CcSEcCtD
Deferiprone—Pruritus—Imiquimod—skin cancer	0.00197	0.00197	CcSEcCtD
Deferiprone—Infection—Bleomycin—skin cancer	0.00196	0.00196	CcSEcCtD
Deferiprone—Nausea—Vemurafenib—skin cancer	0.00194	0.00194	CcSEcCtD
Deferiprone—Diarrhoea—Imiquimod—skin cancer	0.0019	0.0019	CcSEcCtD
Deferiprone—Discomfort—Dactinomycin—skin cancer	0.0019	0.0019	CcSEcCtD
Deferiprone—Pancytopenia—Docetaxel—skin cancer	0.00185	0.00185	CcSEcCtD
Deferiprone—Hypotension—Bleomycin—skin cancer	0.00185	0.00185	CcSEcCtD
Deferiprone—Infection—Dactinomycin—skin cancer	0.00183	0.00183	CcSEcCtD
Deferiprone—Neutropenia—Docetaxel—skin cancer	0.00182	0.00182	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.0018	0.0018	CcSEcCtD
Deferiprone—Weight increased—Docetaxel—skin cancer	0.00177	0.00177	CcSEcCtD
Deferiprone—Convulsion—Temozolomide—skin cancer	0.00177	0.00177	CcSEcCtD
Deferiprone—Vomiting—Imiquimod—skin cancer	0.00177	0.00177	CcSEcCtD
Deferiprone—Hypertension—Temozolomide—skin cancer	0.00176	0.00176	CcSEcCtD
Deferiprone—Rash—Imiquimod—skin cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Dermatitis—Imiquimod—skin cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Pneumonia—Docetaxel—skin cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Headache—Imiquimod—skin cancer	0.00174	0.00174	CcSEcCtD
Deferiprone—Arthralgia—Temozolomide—skin cancer	0.00174	0.00174	CcSEcCtD
Deferiprone—Infestation NOS—Docetaxel—skin cancer	0.00174	0.00174	CcSEcCtD
Deferiprone—Infestation—Docetaxel—skin cancer	0.00174	0.00174	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00173	0.00173	CcSEcCtD
Deferiprone—Discomfort—Temozolomide—skin cancer	0.00172	0.00172	CcSEcCtD
Deferiprone—Decreased appetite—Bleomycin—skin cancer	0.00172	0.00172	CcSEcCtD
Deferiprone—Jaundice—Docetaxel—skin cancer	0.00169	0.00169	CcSEcCtD
Deferiprone—Pain—Bleomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00168	0.00168	CcSEcCtD
Deferiprone—Anaphylactic shock—Temozolomide—skin cancer	0.00167	0.00167	CcSEcCtD
Deferiprone—Infection—Temozolomide—skin cancer	0.00166	0.00166	CcSEcCtD
Deferiprone—Nausea—Imiquimod—skin cancer	0.00165	0.00165	CcSEcCtD
Deferiprone—Hepatobiliary disease—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Deferiprone—Epistaxis—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Deferiprone—Nervous system disorder—Temozolomide—skin cancer	0.00163	0.00163	CcSEcCtD
Deferiprone—Convulsion—Fluorouracil—skin cancer	0.00163	0.00163	CcSEcCtD
Deferiprone—Agranulocytosis—Docetaxel—skin cancer	0.00162	0.00162	CcSEcCtD
Deferiprone—Skin disorder—Temozolomide—skin cancer	0.00162	0.00162	CcSEcCtD
Deferiprone—Hyperhidrosis—Temozolomide—skin cancer	0.00161	0.00161	CcSEcCtD
Deferiprone—Decreased appetite—Dactinomycin—skin cancer	0.0016	0.0016	CcSEcCtD
Deferiprone—Fatigue—Dactinomycin—skin cancer	0.00159	0.00159	CcSEcCtD
Deferiprone—Discomfort—Fluorouracil—skin cancer	0.00158	0.00158	CcSEcCtD
Deferiprone—Pain—Dactinomycin—skin cancer	0.00158	0.00158	CcSEcCtD
Deferiprone—Urticaria—Bleomycin—skin cancer	0.00157	0.00157	CcSEcCtD
Deferiprone—Body temperature increased—Bleomycin—skin cancer	0.00156	0.00156	CcSEcCtD
Deferiprone—Hepatitis—Docetaxel—skin cancer	0.00156	0.00156	CcSEcCtD
Deferiprone—Pharyngitis—Docetaxel—skin cancer	0.00155	0.00155	CcSEcCtD
Deferiprone—Urinary tract disorder—Docetaxel—skin cancer	0.00154	0.00154	CcSEcCtD
Deferiprone—Oedema peripheral—Docetaxel—skin cancer	0.00154	0.00154	CcSEcCtD
Deferiprone—Anaphylactic shock—Fluorouracil—skin cancer	0.00153	0.00153	CcSEcCtD
Deferiprone—Connective tissue disorder—Docetaxel—skin cancer	0.00153	0.00153	CcSEcCtD
Deferiprone—Urethral disorder—Docetaxel—skin cancer	0.00153	0.00153	CcSEcCtD
Deferiprone—Infection—Fluorouracil—skin cancer	0.00152	0.00152	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00152	0.00152	CcSEcCtD
Deferiprone—Gastrointestinal pain—Dactinomycin—skin cancer	0.00151	0.00151	CcSEcCtD
Deferiprone—Nervous system disorder—Fluorouracil—skin cancer	0.00151	0.00151	CcSEcCtD
Deferiprone—Somnolence—Temozolomide—skin cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Dyspepsia—Temozolomide—skin cancer	0.00147	0.00147	CcSEcCtD
Deferiprone—Eye disorder—Docetaxel—skin cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Abdominal pain—Dactinomycin—skin cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Body temperature increased—Dactinomycin—skin cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Hypersensitivity—Bleomycin—skin cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Decreased appetite—Temozolomide—skin cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Cardiac disorder—Docetaxel—skin cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Temozolomide—skin cancer	0.00144	0.00144	CcSEcCtD
Deferiprone—Fatigue—Temozolomide—skin cancer	0.00144	0.00144	CcSEcCtD
Deferiprone—Hypotension—Fluorouracil—skin cancer	0.00143	0.00143	CcSEcCtD
Deferiprone—Pain—Temozolomide—skin cancer	0.00142	0.00142	CcSEcCtD
Deferiprone—Asthenia—Bleomycin—skin cancer	0.00142	0.00142	CcSEcCtD
Deferiprone—Angiopathy—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Deferiprone—Immune system disorder—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Deferiprone—Mediastinal disorder—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Deferiprone—Chills—Docetaxel—skin cancer	0.0014	0.0014	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.0014	0.0014	CcSEcCtD
Deferiprone—Pruritus—Bleomycin—skin cancer	0.0014	0.0014	CcSEcCtD
Deferiprone—Mental disorder—Docetaxel—skin cancer	0.00137	0.00137	CcSEcCtD
Deferiprone—Somnolence—Fluorouracil—skin cancer	0.00136	0.00136	CcSEcCtD
Deferiprone—Gastrointestinal pain—Temozolomide—skin cancer	0.00136	0.00136	CcSEcCtD
Deferiprone—Malnutrition—Docetaxel—skin cancer	0.00136	0.00136	CcSEcCtD
Deferiprone—Hypersensitivity—Dactinomycin—skin cancer	0.00136	0.00136	CcSEcCtD
Deferiprone—Dyspepsia—Fluorouracil—skin cancer	0.00135	0.00135	CcSEcCtD
Deferiprone—Decreased appetite—Fluorouracil—skin cancer	0.00133	0.00133	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00133	0.00133	CcSEcCtD
Deferiprone—Urticaria—Temozolomide—skin cancer	0.00132	0.00132	CcSEcCtD
Deferiprone—Asthenia—Dactinomycin—skin cancer	0.00132	0.00132	CcSEcCtD
Deferiprone—Abdominal pain—Temozolomide—skin cancer	0.00132	0.00132	CcSEcCtD
Deferiprone—Body temperature increased—Temozolomide—skin cancer	0.00132	0.00132	CcSEcCtD
Deferiprone—Back pain—Docetaxel—skin cancer	0.00131	0.00131	CcSEcCtD
Deferiprone—Pain—Fluorouracil—skin cancer	0.00131	0.00131	CcSEcCtD
Deferiprone—Diarrhoea—Dactinomycin—skin cancer	0.00126	0.00126	CcSEcCtD
Deferiprone—Vomiting—Bleomycin—skin cancer	0.00126	0.00126	CcSEcCtD
Deferiprone—Rash—Bleomycin—skin cancer	0.00125	0.00125	CcSEcCtD
Deferiprone—Dermatitis—Bleomycin—skin cancer	0.00124	0.00124	CcSEcCtD
Deferiprone—Hypersensitivity—Temozolomide—skin cancer	0.00123	0.00123	CcSEcCtD
Deferiprone—Urticaria—Fluorouracil—skin cancer	0.00122	0.00122	CcSEcCtD
Deferiprone—Body temperature increased—Fluorouracil—skin cancer	0.00121	0.00121	CcSEcCtD
Deferiprone—Asthenia—Temozolomide—skin cancer	0.0012	0.0012	CcSEcCtD
Deferiprone—Pruritus—Temozolomide—skin cancer	0.00118	0.00118	CcSEcCtD
Deferiprone—Convulsion—Docetaxel—skin cancer	0.00118	0.00118	CcSEcCtD
Deferiprone—Nausea—Bleomycin—skin cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Hypertension—Docetaxel—skin cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Vomiting—Dactinomycin—skin cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Rash—Dactinomycin—skin cancer	0.00116	0.00116	CcSEcCtD
Deferiprone—Arthralgia—Docetaxel—skin cancer	0.00116	0.00116	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00115	0.00115	CcSEcCtD
Deferiprone—Diarrhoea—Temozolomide—skin cancer	0.00114	0.00114	CcSEcCtD
Deferiprone—Hypersensitivity—Fluorouracil—skin cancer	0.00113	0.00113	CcSEcCtD
Deferiprone—Anaphylactic shock—Docetaxel—skin cancer	0.00111	0.00111	CcSEcCtD
Deferiprone—Infection—Docetaxel—skin cancer	0.0011	0.0011	CcSEcCtD
Deferiprone—Nausea—Dactinomycin—skin cancer	0.00109	0.00109	CcSEcCtD
Deferiprone—Nervous system disorder—Docetaxel—skin cancer	0.00109	0.00109	CcSEcCtD
Deferiprone—Pruritus—Fluorouracil—skin cancer	0.00109	0.00109	CcSEcCtD
Deferiprone—Skin disorder—Docetaxel—skin cancer	0.00108	0.00108	CcSEcCtD
Deferiprone—Vomiting—Temozolomide—skin cancer	0.00106	0.00106	CcSEcCtD
Deferiprone—Rash—Temozolomide—skin cancer	0.00105	0.00105	CcSEcCtD
Deferiprone—Diarrhoea—Fluorouracil—skin cancer	0.00105	0.00105	CcSEcCtD
Deferiprone—Dermatitis—Temozolomide—skin cancer	0.00105	0.00105	CcSEcCtD
Deferiprone—Headache—Temozolomide—skin cancer	0.00104	0.00104	CcSEcCtD
Deferiprone—Hypotension—Docetaxel—skin cancer	0.00104	0.00104	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00101	0.00101	CcSEcCtD
Deferiprone—Nausea—Temozolomide—skin cancer	0.00099	0.00099	CcSEcCtD
Deferiprone—Somnolence—Docetaxel—skin cancer	0.000985	0.000985	CcSEcCtD
Deferiprone—Vomiting—Fluorouracil—skin cancer	0.000976	0.000976	CcSEcCtD
Deferiprone—Dyspepsia—Docetaxel—skin cancer	0.000975	0.000975	CcSEcCtD
Deferiprone—Rash—Fluorouracil—skin cancer	0.000968	0.000968	CcSEcCtD
Deferiprone—Dermatitis—Fluorouracil—skin cancer	0.000967	0.000967	CcSEcCtD
Deferiprone—Decreased appetite—Docetaxel—skin cancer	0.000963	0.000963	CcSEcCtD
Deferiprone—Headache—Fluorouracil—skin cancer	0.000962	0.000962	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Docetaxel—skin cancer	0.000956	0.000956	CcSEcCtD
Deferiprone—Fatigue—Docetaxel—skin cancer	0.000955	0.000955	CcSEcCtD
Deferiprone—Pain—Docetaxel—skin cancer	0.000947	0.000947	CcSEcCtD
Deferiprone—Nausea—Fluorouracil—skin cancer	0.000912	0.000912	CcSEcCtD
Deferiprone—Gastrointestinal pain—Docetaxel—skin cancer	0.000906	0.000906	CcSEcCtD
Deferiprone—Abdominal pain—Docetaxel—skin cancer	0.000876	0.000876	CcSEcCtD
Deferiprone—Body temperature increased—Docetaxel—skin cancer	0.000876	0.000876	CcSEcCtD
Deferiprone—Hypersensitivity—Docetaxel—skin cancer	0.000816	0.000816	CcSEcCtD
Deferiprone—Asthenia—Docetaxel—skin cancer	0.000795	0.000795	CcSEcCtD
Deferiprone—Pruritus—Docetaxel—skin cancer	0.000784	0.000784	CcSEcCtD
Deferiprone—Diarrhoea—Docetaxel—skin cancer	0.000758	0.000758	CcSEcCtD
Deferiprone—Vomiting—Docetaxel—skin cancer	0.000704	0.000704	CcSEcCtD
Deferiprone—Rash—Docetaxel—skin cancer	0.000699	0.000699	CcSEcCtD
Deferiprone—Dermatitis—Docetaxel—skin cancer	0.000698	0.000698	CcSEcCtD
Deferiprone—Headache—Docetaxel—skin cancer	0.000694	0.000694	CcSEcCtD
Deferiprone—Nausea—Docetaxel—skin cancer	0.000658	0.000658	CcSEcCtD
